Cited by 386Decision-Making and Behavioral EconomicsSubstance Abuse Treatment and OutcomesNeurotransmitter Receptor Influence on Behavior

The behavioral-and neuro-economic process of temporal discounting: a candidate behavioral marker of addiction

Open access
Bickel, Warren K., Koffarnus, Mikhail N., Moody, Lara, Wilson, A. George·2014·Neuropharmacology

Abstract

Addiction science would benefit from the identification of a behavioral marker. A behavioral marker could reflect the projected clinical course of the disorder, function as a surrogate measure of clinical outcome, and/or may be related to biological components that underlie the disorder. In this paper we review relevant literature, made possible with the early and sustained support by NIDA, to determine whether temporal discounting, a neurobehavioral process derived from behavioral economics and further explored through neuroeconomics, may function as a behavioral marker. Our review suggests that temporal discounting 1) identifies individuals who are drug-dependent, 2) identifies those at risk of developing drug dependence, 3) acts as a gauge of addiction severity, 4) correlates with all stages of addiction development, 5) changes with effective treatment, and 6) may be related to the biological and genetic processes that underlie addiction. Thus, initial evidence supports temporal discounting as a candidate behavioral marker. Additional studies will be required in several areas for a more conclusive determination. Confirmation that temporal discounting functions as a behavioral marker for addiction could lead to 1) a screen for new treatments, 2) personalization of prevention and treatment interventions, and 3) the extension of temporal discounting as a behavioral marker for other etiologically similar disorders. This article is part of a Special Issue entitled 'NIDA 40th Anniversary Issue'.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2013.06.013

Cites

115 of 115 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Delay discounting (DD) refers to the decline in value of a reinforcer as a function of delay and is a process closely related to the phenotype of addiction and other disorders.

    “Delay discounting (DD) refers to the decline in value of a reinforcer as a function of delay and is a process closely related to the phenotype of addiction and other disorders [29].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Bickel, W. K., Koffarnus, M. N., Moody, L., & Wilson, A. G.
Affiliations
Carilion Clinic (US)
Corresponding author
Bickel, Warren K.
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2014-01
Volume
76
Pages
518-527
ISSN
0028-3908 (ISSN-L)
OpenAlex
W2063553039
Cited by
386
References
114
Citations by year
2026: 23 · 2025: 22 · 2024: 20 · 2023: 27 · 2022: 21 · 2021: 33 · 2020: 39 · 2019: 50 · 2018: 26 · 2017: 35 · 2016: 39 · 2015: 31 · 2014: 17 · 2013: 3
FWCI
3.55
Type
journal article
Language
en
Open access
Locations
  • Neuropharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute on Drug Abuse (R01DA024080, R01DA030241, R01DA034755)
  • National Cancer Institute (U19CA157345)
Topics
  • Social Sciences › Decision Sciences › General Decision Sciences › Decision-Making and Behavioral Economics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
delay discounting, addiction, behavioral markers, drug addiction, addiction severity, addiction risk, behavioral economics, neuroeconomics, personalized treatment
MeSH terms
Brain, Choice Behavior, Humans, Behavior, Addictive, Substance-Related Disorders, Economics, Behavioral

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review